Updated 9/6/22
Summary
The Euorpean Society for Medical Oncology (ESMO) takes place from Sept 9-13, 2022 in Paris
ESMO is "the most influential oncology platform designed in Europe"
BPIQ has determined 12 smid-cap biopharmas that are presenting clinical data at the conference
See our Table for info on clinical trial stage, data to be presented, and timing of investor calls
Regular abstracts are available here: Regular abstracts are now available here: https://bit.ly/3APOv5J
See our BPIQ forum post for a more in depth table after subscribing. Includes several new company additions! Learn more here.
The European Society for Medical Oncology (ESMO) has over 25,000 members across 150 countries and holds the ESMO Congress every year. “The ESMO Congress is the most influential oncology platform designed in Europe for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world” according to ESMO. And our experience at BPIQ/Amp confirms that this is an important meeting every September for cancer, and for smid-cap biopharma investors.
ESMO22 starts September 9, 2022 and extends through September 13. The online platform will be open through September 20. Browse the full ESMO22 program HERE.
Every year, upon abstract release and as a result of presentations at the conference, some biopharma stocks move significantly because they report important clinical trial updates. Abstracts for regular presentations at ESMO22 will be released Septmber 5 at 12:05am CEST and late breaking abstracts will be released September 8 at 12:05am CEST. Here is a link to the abstracts, which are now available: https://bit.ly/3APOv5J. In fact, at that link, if you search the top right search box abstracts from prior ESMO conferences are available too. If you just want to search ESMO '22 abstracts use the search box down further on the page below "Filter by".
Positive clinical trial results in a single trial can have a significant impact on the underlying stock price. This is especially true for biopharma companies with market caps under $5 billion, who typically have far less clinical and approved assets than larger companies, and thus whose valuation can be more affected by a single drug candidate and trial. The clinical assets of these micro, small and mid-cap cancer biopharma companies are a primary driver for the development of future cancer therapies.
To this end, our team updated and scoured through our BPIQ database to identify biopharma companies that are presenting clinical trial updates at ESMO22. Table 1 lists those companies in our BPIQ database that are presenting clinical update(s) at ESMO22. Most of these companies are smid-cap biopharmas, but $AMGN was also included in the list because of the important KRAS trial that was recently added as a late breaker presentation. The Ph3 Codebreak-200 trial reported topline data on 8/30/22 and was granted a last-minute spot at ESMO 2022.
See Table 1 for introductory info on these companies and keep an eye out for more details to come surrounding presentation data.
Table 1. BPIQ.com smid-cap biopharma companies presenting clinical updates at ESMO22
The question for biopharma investors now with respect to ESMO22 is which stocks or groups of stocks are likely to move upon the release of the ESMO22 abstract, poster, oral presentation, or associated investor meeting. We plan to continue to analyze the current trial data from ESMO22 companies as well as the abstracts, once released, and plan to update this information on BPIQ.com. In the meantime, the information provided in this article provides an interesting snapshot into the smid-cap biopharma companies that are developing some of our most exciting future medicines. For investors, these companies represent an exciting opportunity for further diligence and possible investment.
See our BPIQ forum post for a more in depth table after subscribing. Learn more here.
This article is NOT legal, investment or tax advice. Please do your own diligence before making any investments.
#RLAY #RLY4008 #HCM #Fruquintinib #AYLA #AL102 #SWTX #Nirogacestat #PSTV #186RNL #IMAB #Lemzoparlimab #GRTS #SLATE #SPPI #Poziotinib #ZYME #ZW49 #IMCR #IMCF106C #NGM #NGM120 #DCPH #Vimseltinib #AMGN #Lumakras
Article history:
Originally posted 9/1/22